Andy Health blog

Men’s Health News
Men who develop diabetes in mid-life appear to significantly increase their risk of developing Alzheimer’s disease, according to a long-term study published in the April 9, 2008, online issue of Neurology, the medical journal of the American Academy of Neurology.
"Our results have important public health implications given the increasing numbers of people developing diabetes and the need for more powerful interventions," said study author Elina R?nnemaa, MD, with Uppsala University in Uppsala, Sweden.
The study involved 2,269 men in Sweden who underwent glucose testing at age 50 to test for diabetes, which is caused by abnormal insulin levels. During an average follow up of 32 years, 102 participants were diagnosed with Alzheimer’s disease, 57 with vascular dementia and 235 with other types of dementia or cognitive impairment.
The study found that the men with low insulin secretion capacity at age 50 were nearly one-and-a-half times more likely to develop Alzheimer’s disease than people without insulin problems. The risk remained significant regardless of blood pressure, cholesterol, body mass index and education.
"Our results suggest a link between insulin problems and the origins of Alzheimer’s disease and emphasize the importance of insulin in normal brain function," said R?nnemaa. "It’s possible that insulin problems damage blood vessels in the brain, which leads to memory problems and Alzheimer’s disease, but more research is needed to identify the exact mechanisms."
Buy generic cialis The study also found the association between diabetes and risk of Alzheimer’s disease was strongest in people who did not have the APOE4 gene, which is known to increase the risk of Alzheimer’s disease. R?nnemaa says this shows that insulin problems are an important risk factor for Alzheimer’s disease when the high risk gene is missing.

Buy generic clomid | generic cialis online buy | Generic zithromax pills no prescription

Cook Medical , announced the launch of www.MensHealthPD.com, an informational microsite dedicated to educating physicians, men and their partners about the symptoms, treatment options and latest research on Peyronie’s disease, a common form of erectile dysfunction thought to affect more than 80, 000 men in the UK, with one study suggesting 1% of the male population may suffer. MensHealthPD.com is designed to provide the latest information on the painful ailment and also offers medical professionals, patients and their partners public and physician forums for discussing the disease, posting questions and sharing personal experiences about the condition.
For many men and their partners, erectile dysfunctions, such as Peyronie’s disease, are embarrassing and uncomfortable to discuss. It is also often difficult to find a centralised repository on the web with the helpful information needed to obtain answers on these conditions. MensHealthPD.com is changing all this by offering these individuals a one-stop, discreet Peyronie’s resource armed with the following assets:
- Video answers to the most commonly asked questions about Peyronie’s disease provided by some the world’s leading Peyronie’s doctor experts.
- A Q&A forum where patients, partners and doctors can discuss available Peyronie’s treatments, exchange ideas on coping with the disease and more.
- Details of the signs, symptoms and progression of Peyronie’s disease.
- A helpful list of questions to prepare a man afflicted with Peyronie’s for his first doctor’s visit
Many men living with Peyronie’s disease go untreated because so few GPs understand the disease. In fact, a recent study showed that over half of primary care physicians were unsure any effective treatments for the disease existed. Therefore, many men never get referred to a urologist who may be able to treat the condition.
Buy diflucan pills MensHealthPD.com will serve as a single source where GPs, urologists and other physicians from around the world can access the latest peer-reviewed research on Peyronie’s treatment options as well as other relevant published scientific data. The following resources are available on the microsite to educate these doctors on the wide array of treatment options available for Peyronie’s sufferers:
- A summary of current surgical and non-surgical treatment options with links to the most current published research.
- The latest peer-reviewed research on Peyronie’s disease posted in the MEDLINE database of citations and abstracts and indexed through PubMed, offered by the US National Library of Medicine and the National Institutes of Health (NIH).
- A secure, physicians-only Q&A forum where doctors can share best practices and increase their collective knowledge with their colleagues.
Raj Persad, a Consultant Urologist at United Bristol Healthcare NHS explains: "This is a distressing disease with huge potential psychosexual impact. In an area such as this where treatment options for different stages of the disease are limited and often confusing for patients we need to share as much information as possible about new management options. This website will benefit both clinicians and patients alike in enabling the sharing of experience and information which could be of benefit to all’
About Peyronie’s Disease
Peyronie’s disease, also known as penile curvature, is estimated to affect nearly four out of every 100 males between the ages 45 and 65[3]. The disease is linked to erectile dysfunction in 20 to 40 percent of the sufferers and is characterised by the formation of a plaque or hardened scar tissue beneath the skin of a man’s penis. The scarring is non-cancerous and may lead to a painful erection and curvature of the penis during erection.

Buy diflucan pills | Generic lexapro pills no prescription | Buy amoxil without prescription

At the request of the U.S. Food and Drug Administration, U.S. Marshals seized more than 14,000 dosage units of Shangai Regular, Shangai Ultra, Super Shangai, Natural?« Super Plus, and Lady Shangai. Although labeled as natural supplements, the seized products were all marketed to treat erectile dysfunction (ED), impotency, and/or to provide sexual enhancement, which caused them to be drugs under the Federal Food, Drug, and Cosmetic Act.
The seized products, valued at more than $100,000, contain undeclared active ingredients found in FDA-approved prescription drugs for ED, or similar substances. Use of these products may result in serious side effects and may interact in dangerous ways with medications that a consumer may already be taking.
"The FDA will not tolerate companies marketing unapproved drugs — products that have not proven to be safe or effective — as dietary supplements," said Margaret O’K. Glavin, associate commissioner for regulatory affairs. "The agency will pursue necessary legal action to make sure companies and their executives manufacture and distribute safe drug products."
The seized products, which originated in China, are packaged and distributed by Shangai Distributors, Inc. of Coamo, Puerto Rico. Buy generic ultram Although the products’ labels state they are natural supplements, these products are drugs and their sale is illegal without FDA approval. Before a new drug product may be legally marketed, it must be shown to be safe and effective.
In response to a consumer complaint, the FDA conducted an inspection of Shangai Distributors Inc., in November 2007. The FDA’s investigation and testing revealed that the seized products contained active drug ingredients found in FDA-approved ED prescription drugs and/or a substance with a structure similar to such drugs that may cause similar side effects and drug interactions. None of the drug ingredients are listed on the labels of any of the seized products.
The undeclared ingredients in these products may interact with nitrates found in some prescription drugs (such as nitroglycerin) and can lower blood pressure to dangerous levels. Consumers with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. ED is a common problem in men with these medical conditions. Because they may have been advised against taking ED drugs, they may seek out products like these because they are marketed as "all natural" or as not containing the active ingredients in approved, prescribed ED drugs. Additionally, because the manufacturing source of the active ingredients in these products is unknown, consumers should be aware that the safety, efficacy, and purity of these ingredients can not be validated.
Despite being advised of the findings and the potential adverse health risk posed by the seized products and that regulatory action was possible, the company did not take any action to correct the violations. The FDA issued a press release on December 28, 2007 advising consumers not to buy or use the products. Prior to the seizure, the Puerto Rico Department of Health embargoed the seized products to protect the citizens of Puerto Rico and to support the FDA’s enforcement actions.
The FDA advises consumers who have used any of these products to discontinue use and consult their health care providers if they have experienced any adverse events that they believe are related to the use of these products. Consumers and health care professionals can report adverse events to FDA’s MedWatch program at 800-FDA-1088 or online at FDA recommends that consumers talk to their health care provider about FDA-approved treatments for erectile dysfunction. FDA may take further regulatory actions to protect consumers from these illegal products.
The complaint was filed by Assistant U.S. Attorney Jose M. Pizarro, deputy chief, Civil Division, United States Attorney’s Office, District of Puerto Rico.

Buy soma without prescription | Generic synthroid pills no prescription | Buy generic ultram

Buy generic cipro Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuticals, Inc.
(NYSE: KG) announced today that they have delayed plans for the initiation
of Phase 3 clinical trials with bremelanotide, a first in class
melanocortin agonist drug candidate, for the treatment of male erectile
dysfunction (ED). The decision follows responses from representatives of
the U.S. Food and Drug Administration (FDA), which raised serious concerns
about the acceptable benefit/risk ratio to support the progression of the
proposed program into Phase 3 studies for ED.
After reviewing the data generated in the Phase 1 and 2 studies, the
FDA questioned the overall efficacy results and the clinical benefit of
this product in both the general and diabetic ED populations, and cited
blood pressure increases as its greatest safety concern. Though not
supportive of the proposed Phase 3 studies for ED with bremelanotide, the
FDA stated that it was amenable to proposals for a different drug
development pathway, such as for a second-line therapy in non-responders to
currently approved PDE-5 inhibitors.
"The safety of patients in our clinical program has always been our
number one priority and we will work closely with the FDA, King, and our
advisors to determine the next steps for the program," stated Carl Spana,
Ph.D., President and Chief Executive Officer of Palatin.
Palatin and King plan to review the FDA comments in the overall context
of the program in order to determine next steps related to the further
development of bremelanotide for the treatment of ED.
About ED
ED is defined as the consistent inability to attain and maintain an
erection sufficient for sexual intercourse. The condition is correlated
with increasing age, cardiovascular disease, hypertension, diabetes,
hyperlipidemia, and smoking. In addition, certain prescription drugs and
psychogenic issues may contribute to ED. It is estimated that some degree
of ED affects one half of all men over the age of 40 and that 150 million
men worldwide suffer from ED.
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company focused on
discovering and developing targeted, receptor-specific small molecule and
peptide therapeutics. Palatin’s internal research and development
capabilities, anchored by its proprietary MIDAS(TM) technology, are fueling
product development. Palatin’s strategy is to develop products and then
form marketing collaborations with industry leaders in order to maximize
their commercial potential. To date, Palatin has entered into
collaborations with AstraZeneca, King Pharmaceuticals, and Tyco Healthcare
Mallinckrodt. For additional information regarding Palatin, please visit
Palatin Technologies’ website at
About King Pharmaceuticals, Inc.
King, headquartered in Bristol, Tennessee, is a vertically integrated
branded pharmaceutical company. King, an S&P 500 Index company, seeks to
capitalize on opportunities in the pharmaceutical industry through the
development, including through in-licensing arrangements and acquisitions,
of novel branded prescription pharmaceutical products in attractive markets
and the strategic acquisition of branded products that can benefit from
focused promotion and marketing and product life-cycle management.
Palatin Technologies, Inc

generic lasix online buy | generic propecia online buy | Buy generic diflucan

Men’s Health News
An Oregon Health & Science University Cancer Institute researcher has identified a protein that is a strong indicator of survival for men with advanced prostate cancer. The C-reactive protein, also known as CRP, is a special type of protein produced by the liver that is elevated in the presence of inflammation.
"This could mean that a simple blood test that is already available could help in clinical decision making and patient counseling. Patients and doctors would know better what to expect from the prostate cancer they are facing," said Tomasz Beer, M.D., director of the Prostate Cancer Research Program at the OHSU Cancer Institute, associate professor of medicine (hematology/medical oncology), OHSU School of Medicine.
Beer’s research will be published online in the journal Cancer on Monday, April 21.
Past research has shown that cancer causes an inflammatory response. This research also suggests that inflammation may play an important role in driving prostate cancer progression and resistance to therapy. Inflammatory cells are attracted to cancer sites and this local inflammation can lead to a release of inflammatory markers, like CRP.
"While inflammation may sometimes slow the progression of the cancer, an increasing body of evidence suggests that cancer can actually take advantage of the inflammatory response, and the reaction of the immune system may fuel cancer progression. To the extent that our hypothesis proves true, C-reactive protein may be reflecting the overall intensity of the inflammation," Beer said.
Buy generic lasix The finding that higher CRP is associated with shorter survival and a lower probability of response to chemotherapy is a result of a secondary analysis of inflammatory markers in patients enrolled in the ASCENT study, a large Phase 2 clinical trial that evaluated treatment with docetaxel and DN-101, a high dose formulation of calcitriol or docetaxel with placebo. This analysis included patients from both groups. The analyses were supported by Novacea Inc., the sponsor of the ASCENT study. This new finding was in collaboration with Novacea.
Because this is the first time CRP has been linked with both response and survival in study subjects with advanced prostate cancer receiving chemotherapy, it will be important to confirm this finding in an independent data set before this can become a routine blood test for men with advanced prostate cancer, Beer explained.
"If confirmed, besides providing useful information for the patient, this finding could also provide us with vital insight into the fundamental role of inflammation in the progression of advanced prostate cancer. A better understanding of this process could provide us with novel therapeutic interventions for control of this disease and its symptoms," Beer said.

Buy clomid pills | Buy levitra pills | generic viagra online buy